Moderna Stock Surges 6%  on Expectations of Up to $15 Billion in Sales From New Drugs
<p><a href='https://financialmodelingprep.com/financial-summary/MRNA'>Moderna (NASDAQ:MRNA)</a> shares gained more than 6% intra-day today after the company revealed its projection of generating $10 billion to $15 billion in annual sales from new drugs by 2028.</p>
<p>In addition to this, the drugmaker expects to achieve $8 billion to $15 billion in sales from the respiratory franchise by 2027, as previously announced. Moderna also anticipates COVID-19 vaccine sales ranging from $6 billion to $8 billion in 2023, with specific figures contingent on U.S. vaccination rates. </p>
<p>Furthermore, the company reported the successful outcome of its Phase 3 trial for the flu vaccine mRNA-1010.</p>

NASDAQ:MRNA